Abstract
Introduction
Datamonitor expects antidiabetic therapies to emerge as the biggest revenue
earner in the cardiovascular and metabolic markets by 2017. A large and
diverse development pipeline will provide a number of new blockbuster drugs
but the heavy genericization of the hypertension and dyslipidemia primary care
markets will lead to the overall market only growing by 0.9% in the seven
major markets.
Key reasons to purchase this research
- A detailed clinical and commercial assessment of all key cardiovascular
and metabolic therapy areas.
- An analysis of the portfolios of top 10 leading cardiovascular and
metabolic companies.
- Sales based sales forecasts for all key cardiovascular and metabolic
active agents in the seven major markets to 2017.
| 
View Cart
